Abstract

BackgroundVancomycin is commonly used to treat Enterococcus faecium (E. faecium) bacteremia. However, there are very few studies on the association between the trough concentration, area under the curve from 0 to 24 h /minimum inhibitory concentration (AUC24/MIC) ratio, and the therapeutic effect of vancomycin on E. faecium bacteremia. This study aimed to investigate the associations between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with E. faecium bacteremia.MethodsThis retrospective study included patients with E. faecium bacteremia who received vancomycin between April 2012 and February 2018 at a single acute care hospital in Japan. Patients who received renal replacement therapy (hemodialysis or continuous hemodiafiltration), had an unmeasured serum vancomycin concentration, with unmeasured laboratory values, or received other antibiotics for treating E. faecium bacteremia were excluded from the study. The bivariate associations between 30-day all-cause mortality and patient characteristics were assessed.ResultsAmong 87 patients diagnosed with E. faecium bacteremia, 45 were included in the final analysis. Of these, 12 (26.7%) died within 30 days of the diagnosis. The vancomycin trough concentration was higher in the 30-day all-cause mortality patients than in the survival patients (20.5 vs. 14.6 μg/mL; P = 0.022). There was no significant difference in the proportion of patients with a vancomycin AUC24/MIC ≤389 between the groups. The 30-day all-cause mortality patients showed a higher Charlson Comorbidity Index (CCI) and Sequential Organ Failure Assessment score at the first measurement of the vancomycin trough concentration than the survival patients. The same finding was observed among patients with a high CCI score (≥5 points).ConclusionsWhereas the vancomycin trough concentration and AUC24/MIC ratio were not associated with mortality in patients with E. faecium bacteremia, disease severity was associated with mortality in these patients.

Highlights

  • Vancomycin is commonly used to treat Enterococcus faecium (E. faecium) bacteremia

  • A recent report showed that an area under the curve (AUC)/minimum inhibitory concentration (MIC) ≥389 was associated with reduced mortality for various Enterococcus bacteremias [7]; few studies on the association between the vancomycin trough concentration or AUC/MIC ratio and the therapeutic effect against only E. faecium bacteremia have been conducted

  • We investigated the associations between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with E. faecium bacteremia

Read more

Summary

Introduction

There are very few studies on the association between the trough concentration, area under the curve from 0 to 24 h /minimum inhibitory concentration (AUC24/MIC) ratio, and the therapeutic effect of vancomycin on E. faecium bacteremia. Previous studies have determined the appropriate target trough concentrations or area under the curve (AUC)/ minimum inhibitory concentration (MIC) ratios of vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) and reported the association between the vancomycin trough concentration or AUC/ MIC ratio and vancomycin’s therapeutic effect against MRSA bacteremia. A recent report showed that an AUC/MIC ≥389 was associated with reduced mortality for various Enterococcus bacteremias [7]; few studies on the association between the vancomycin trough concentration or AUC/MIC ratio and the therapeutic effect against only E. faecium bacteremia have been conducted

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call